27 domestic innovative drugs will be launched in 2021, reaching new heights

 The year 2021, which has just passed, is the first year of the national "14th Five-Year Plan", and it is also a key year for China's new round of medical reform to enter the "deep water area"
.
It is understood that under the impetus of the medical reform policy, the R&D enthusiasm of China's pharmaceutical enterprises continues to rise, and it is developing in the direction of innovation
.
Statistics show that in the first three quarters of 2021, more than 80% of China's A-share listed pharmaceutical companies have increased their R&D investment
.
Among them, six pharmaceutical companies, including Hengrui Pharmaceutical, Fosun Pharmaceutical, Mindray Medical, Junshi Bio, Shanghai Pharmaceuticals, and Kelun Pharmaceutical, have invested more than 1 billion yuan in research and development
.
Taking Hengrui Medicine as an example, in recent years, Hengrui Medicine's R&D investment has maintained rapid growth year after year.
Among them, Hengrui Medicine's R&D investment in 2020 will reach nearly 5 billion yuan, and in the first three quarters of 2021, it has exceeded 4 billion yuan, and R & D investment accounts for revenue.
of more than 20%
.
It is understood that under the continuous and high-intensity R&D investment, Hengrui Medicine's talents and scientific research system are increasingly improved.
The company has built a large-scale and professional global R&D team of more than 4,500 people, and established a national enterprise technology center and postdoctoral scientific research.
Workstations, National Molecular Targeted Drug Engineering Research Center, "National Major New Drug Creation" special incubator base and other scientific and technological platforms have laid a solid foundation for the continuous output of high-quality R&D results
.
In the process of development, Fosun Pharma has also continuously strengthened its innovative R&D and BD capabilities, enriched and consolidated its product lines, continued to promote the development and implementation of innovative products and technologies, and strengthened its commercialization system
.
Data show that in the first three quarters of 2021, Fosun Pharma invested 3.
151 billion yuan in research and development, a year-on-year increase of 15.
46%
.
Among them, research and development expenses were 2.
414 billion yuan, a year-on-year increase of 28.
54%
.
In the first three quarters of 2021, Junshi Bio's R&D expenses increased to 1.
423 billion yuan
.
According to Junshi Bio's 2021 semi-annual report, the company is in an important R&D investment period.
With the further enrichment of product pipelines and the rapid advancement of clinical trials of products under development both domestically and internationally, it will continue to invest a lot of R&D expenses
.
Shanghai Pharmaceuticals, in the first three quarters, invested 1.
715 billion in research and development, and spent 1.
367 billion in research and development, a year-on-year increase of 45.
6% and 31.
38% respectively
.
It is reported that there are currently 39 projects in the R&D pipeline of Shanghai Pharmaceuticals, and 6 projects are in clinical phase III.
In the future, the self-operated + BD two-wheel drive will continue to promote the progress of the pipeline
.
In addition, the R&D investment of Mindray Medical and Kelun Pharmaceutical in the first three quarters of 2021 was 1.
629 billion yuan and 1.
189 billion yuan respectively, an increase of 20.
64% and 18.
97% respectively over the same period of the previous year
.
In addition to the above companies, nearly 70 pharmaceutical companies have invested more in research and development in the first three quarters of 2021 than in the whole of 2020
.
It is understood that with the support of policies and the increased research and development of enterprises, the Chinese pharmaceutical market is transforming into an innovation-driven market.
Data shows that the approval of domestic innovative drugs in 2021 will show a blowout trend, and the National Medical Products Administration (NMPA) has approved a total of 76 models.
New drugs (excluding new indications and vaccines) are listed, including Cyclopofol Injection, Ainovirine Tablets, Hetrombopag Ethanolamine Tablets, Hypermedib Tablets, Sivotinib Tablets, Levoornidazole Phosphate for Injection Hengrui Medicine, Baiji, Hansoh and many other pharmaceutical companies are deployed for blockbuster drugs such as disodium esters, which involve urgently needed clinical treatment drugs in the fields of tumors, vaccines, and rare diseases
.
Among them, 27 domestic innovative drugs will be launched in 2021, hitting a new high in the past three years
.
According to NMPA data, in 2020, 20 varieties of innovative drugs have been approved for production, compared with 14 in 2019
.
According to industry insiders, the continuous approval and marketing of innovative drugs will not only achieve breakthroughs in the field of major diseases and benefit patients, but also reduce dependence on new foreign drugs
.
And the successful research and development of a drug will also bring huge returns to the company, prompting most companies to be willing to invest in the chain effect
.